Mini-beam as salvage chemotherapy for refractory hodgkin's disease and non-hodgkin's lymphoma

Alexander Keith Stewart, Joseph M. Brandwein, Simon B. Sutcliffe, J. Gerald Scott, Armand Keating

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Long-term disease-free survival after conventional dose salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) is rare. Intensive chemotherapy and autologous bone marrow transplantation (ABMT) is regarded by many as the treatment of choice. For lymphoma, eligibility for transplant is frequently restricted to cases with chemotherapy-sensitive disease or minimal tumour bulk. We evaluated the mini-BEAM regimen as further treatment for patients unresponsive to initial salvage therapy and thus ineligible for ABMT at our centre. Carmustine 60 mg/m2 I.V. day one, etoposide 75 mg/m2 I.V. days 2-5, cytosine arabinoside 100 mg/m2 I.V. q12h days 2-5 and melphalan 30 mg/m2 day 6 (mini-BEAM) was administered to 24 patients with lymphoma, 22 of whom were refractory to at least first-line salvage chemotherapy. Eleven had HD and 13 NHL. The complete response (CR) rate was 21% and the overall response was 59%. Febrile neutropenia occurred in 48% of treatment episodes. There were two treatment-related deaths. Thirteen patients underwent bone marrow transplantation (BMT), 11 received ABMT (8 HD, 3 NHL). Six patients did not achieve remission after transplant but 7 patients remain in continuous CR, with a follow-up of 6-17 months post-transplant. Consequently, 7 of 24 (29%) patients responded to mini-BEAM and many achieve long-term disease-free survival after BMT. Further evaluation of mini-BEAM as a salvage regimen prior to BMT is indicated.

Original languageEnglish (US)
Pages (from-to)111-115
Number of pages5
JournalLeukemia and Lymphoma
Volume5
Issue number2-3
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Bone Marrow Transplantation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Drug Therapy
Autologous Transplantation
Transplants
Disease-Free Survival
Lymphoma
Carmustine
Salvage Therapy
Febrile Neutropenia
Melphalan
Cytarabine
Etoposide
Therapeutics
Neoplasms

Keywords

  • MiniBEAM
  • Refractory Hodgkin's disease
  • Refractory non-Hodgkin's lymphoma
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mini-beam as salvage chemotherapy for refractory hodgkin's disease and non-hodgkin's lymphoma. / Stewart, Alexander Keith; Brandwein, Joseph M.; Sutcliffe, Simon B.; Scott, J. Gerald; Keating, Armand.

In: Leukemia and Lymphoma, Vol. 5, No. 2-3, 1991, p. 111-115.

Research output: Contribution to journalArticle

Stewart, Alexander Keith ; Brandwein, Joseph M. ; Sutcliffe, Simon B. ; Scott, J. Gerald ; Keating, Armand. / Mini-beam as salvage chemotherapy for refractory hodgkin's disease and non-hodgkin's lymphoma. In: Leukemia and Lymphoma. 1991 ; Vol. 5, No. 2-3. pp. 111-115.
@article{cc12edaf5c1c44b19ad4e8fa82a8b011,
title = "Mini-beam as salvage chemotherapy for refractory hodgkin's disease and non-hodgkin's lymphoma",
abstract = "Long-term disease-free survival after conventional dose salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) is rare. Intensive chemotherapy and autologous bone marrow transplantation (ABMT) is regarded by many as the treatment of choice. For lymphoma, eligibility for transplant is frequently restricted to cases with chemotherapy-sensitive disease or minimal tumour bulk. We evaluated the mini-BEAM regimen as further treatment for patients unresponsive to initial salvage therapy and thus ineligible for ABMT at our centre. Carmustine 60 mg/m2 I.V. day one, etoposide 75 mg/m2 I.V. days 2-5, cytosine arabinoside 100 mg/m2 I.V. q12h days 2-5 and melphalan 30 mg/m2 day 6 (mini-BEAM) was administered to 24 patients with lymphoma, 22 of whom were refractory to at least first-line salvage chemotherapy. Eleven had HD and 13 NHL. The complete response (CR) rate was 21{\%} and the overall response was 59{\%}. Febrile neutropenia occurred in 48{\%} of treatment episodes. There were two treatment-related deaths. Thirteen patients underwent bone marrow transplantation (BMT), 11 received ABMT (8 HD, 3 NHL). Six patients did not achieve remission after transplant but 7 patients remain in continuous CR, with a follow-up of 6-17 months post-transplant. Consequently, 7 of 24 (29{\%}) patients responded to mini-BEAM and many achieve long-term disease-free survival after BMT. Further evaluation of mini-BEAM as a salvage regimen prior to BMT is indicated.",
keywords = "MiniBEAM, Refractory Hodgkin's disease, Refractory non-Hodgkin's lymphoma, Salvage chemotherapy",
author = "Stewart, {Alexander Keith} and Brandwein, {Joseph M.} and Sutcliffe, {Simon B.} and Scott, {J. Gerald} and Armand Keating",
year = "1991",
doi = "10.3109/10428199109068113",
language = "English (US)",
volume = "5",
pages = "111--115",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2-3",

}

TY - JOUR

T1 - Mini-beam as salvage chemotherapy for refractory hodgkin's disease and non-hodgkin's lymphoma

AU - Stewart, Alexander Keith

AU - Brandwein, Joseph M.

AU - Sutcliffe, Simon B.

AU - Scott, J. Gerald

AU - Keating, Armand

PY - 1991

Y1 - 1991

N2 - Long-term disease-free survival after conventional dose salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) is rare. Intensive chemotherapy and autologous bone marrow transplantation (ABMT) is regarded by many as the treatment of choice. For lymphoma, eligibility for transplant is frequently restricted to cases with chemotherapy-sensitive disease or minimal tumour bulk. We evaluated the mini-BEAM regimen as further treatment for patients unresponsive to initial salvage therapy and thus ineligible for ABMT at our centre. Carmustine 60 mg/m2 I.V. day one, etoposide 75 mg/m2 I.V. days 2-5, cytosine arabinoside 100 mg/m2 I.V. q12h days 2-5 and melphalan 30 mg/m2 day 6 (mini-BEAM) was administered to 24 patients with lymphoma, 22 of whom were refractory to at least first-line salvage chemotherapy. Eleven had HD and 13 NHL. The complete response (CR) rate was 21% and the overall response was 59%. Febrile neutropenia occurred in 48% of treatment episodes. There were two treatment-related deaths. Thirteen patients underwent bone marrow transplantation (BMT), 11 received ABMT (8 HD, 3 NHL). Six patients did not achieve remission after transplant but 7 patients remain in continuous CR, with a follow-up of 6-17 months post-transplant. Consequently, 7 of 24 (29%) patients responded to mini-BEAM and many achieve long-term disease-free survival after BMT. Further evaluation of mini-BEAM as a salvage regimen prior to BMT is indicated.

AB - Long-term disease-free survival after conventional dose salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) is rare. Intensive chemotherapy and autologous bone marrow transplantation (ABMT) is regarded by many as the treatment of choice. For lymphoma, eligibility for transplant is frequently restricted to cases with chemotherapy-sensitive disease or minimal tumour bulk. We evaluated the mini-BEAM regimen as further treatment for patients unresponsive to initial salvage therapy and thus ineligible for ABMT at our centre. Carmustine 60 mg/m2 I.V. day one, etoposide 75 mg/m2 I.V. days 2-5, cytosine arabinoside 100 mg/m2 I.V. q12h days 2-5 and melphalan 30 mg/m2 day 6 (mini-BEAM) was administered to 24 patients with lymphoma, 22 of whom were refractory to at least first-line salvage chemotherapy. Eleven had HD and 13 NHL. The complete response (CR) rate was 21% and the overall response was 59%. Febrile neutropenia occurred in 48% of treatment episodes. There were two treatment-related deaths. Thirteen patients underwent bone marrow transplantation (BMT), 11 received ABMT (8 HD, 3 NHL). Six patients did not achieve remission after transplant but 7 patients remain in continuous CR, with a follow-up of 6-17 months post-transplant. Consequently, 7 of 24 (29%) patients responded to mini-BEAM and many achieve long-term disease-free survival after BMT. Further evaluation of mini-BEAM as a salvage regimen prior to BMT is indicated.

KW - MiniBEAM

KW - Refractory Hodgkin's disease

KW - Refractory non-Hodgkin's lymphoma

KW - Salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0025915995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025915995&partnerID=8YFLogxK

U2 - 10.3109/10428199109068113

DO - 10.3109/10428199109068113

M3 - Article

AN - SCOPUS:0025915995

VL - 5

SP - 111

EP - 115

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2-3

ER -